1. Arsenic Trioxide Controls the Fate of the PML-RARα Oncoprotein by Directly Binding PML.
- Author
-
Xiao-Wei Zhang, Xiao-Jing Yan, Zi-Ren Zhou, Fei-Fei Yang, Zi-Yu Wu, Hong-Bin Sun, Wen-Xue Liang, Ai-Xin Song, Lallemand-Breitenbach, Valerie, Jeanne, Marion, Qun-Ye Zhang, Huai-Yu Yang, Qiu-Hua Huang, Guang-Biao Zhou, Jian-Hua Tong, Yan Zhang, Ji-Hui Wu, Hong-Yu Hu, de Thé, Hugues, and Sai-Juan Chen
- Subjects
- *
THERAPEUTIC use of arsenic , *LEUKEMIA treatment , *ARSENIC trioxide , *DENATURATION of proteins , *ONCOGENES , *ACUTE diseases , *CHINESE medicine - Abstract
Arsenic, an ancient drug used in traditional Chinese medicine, has attracted worldwide interest because it shows substantial anticancer activity in patients with acute promyelocytic leukemia (APL). Arsenic trioxide (As2O3) exerts its therapeutic effect by promoting degradation of an oncogenic protein that drives the growth of APL cells, PML-RARα (a fusion protein containing sequences from the PML zinc finger protein and retinoic acid receptor alpha). PML and PML-RARα degradation is triggered by their SUMOylation, but the mechanism by which As2O3induces this posttranslational modification is unclear. Here we show that arsenic binds directly to cysteine residues in zinc fingers located within the RBCC domain of PML-RARα and PML. Arsenic binding induces PML oligomerization, which increases its interaction with the small ubiquitin-like protein modifier (SUMO)--conjugating enzyme UBC9, resulting in enhanced SUMOylation and degradation. The identification of PML as a direct target of As2O3 provides new insights into the drug's mechanism of action and its specificity for APL. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF